Comparative Pharmacology
Head-to-head clinical analysis: FILSPARI versus SACUBITRIL AND VALSARTAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FILSPARI versus SACUBITRIL AND VALSARTAN.
FILSPARI vs SACUBITRIL AND VALSARTAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FILSPARI (sparsentan) is an endothelin receptor antagonist (ERA) and angiotensin II receptor blocker (ARB) with high affinity for the endothelin type A (ETA) receptor and angiotensin II type 1 (AT1) receptor. It reduces proteinuria in IgA nephropathy by inhibiting endothelin-1 mediated vasoconstriction, inflammation, and fibrosis, and by blocking angiotensin II mediated effects.
Sacubitril inhibits neprilysin, increasing natriuretic peptides; Valsartan blocks angiotensin II type 1 receptor, reducing vasoconstriction and aldosterone release. Combined, they enhance vasodilation, decrease sympathetic activity, and reduce cardiac remodeling.
200 mg orally once daily, with or without food.
Initial dose: 24 mg/26 mg (sacubitril 24 mg/valsartan 26 mg) orally twice daily, then double at 2- to 4-week intervals to target maintenance dose of 97 mg/103 mg twice daily.
None Documented
None Documented
Terminal half-life ~30 hours in healthy subjects, supporting once-daily dosing.
Sacubitrilat terminal half-life is approximately 11.5 hours; valsartan terminal half-life is approximately 9.9 hours. Twice-daily dosing maintains therapeutic concentrations.
Primarily hepatic metabolism; <1% excreted unchanged in urine. ~59% of dose recovered in feces and ~27% in urine as metabolites.
Sacubitril is converted to sacubitrilat, which is primarily eliminated renally (52–68% as sacubitrilat) and via biliary/fecal routes (37–48% as metabolites). Valsartan is predominantly eliminated via biliary/fecal route (83%) with renal elimination accounting for 13%.
Category C
Category D/X
Endothelin Receptor Antagonist / ARB
ARB